GlycoMimetics Inc 2025年季度报告

OR PART I. FINANCIAL INFORMATION Balance Sheets as of March 31, 2025 (unaudited) and December31, 20243Unaudited Statements of Operations and Comprehensive Loss for the three months Unaudited Statements of Stockholders’ Equity for the three months ended March 31, 2025 and 2024 Unaudited Statements of Cash Flows for the three months ended March 31, 2025 and20246 ITEM1. FINANCIAL STATEMENTS GlycoMimetics, Inc. (the Company), a Delaware corporation, was incorporated in 2003. TheCompany was previously developing a pipeline of proprietary glycomimetics, which are small Accrued research and development expensesAccrued consulting and other professional fees Accrued employee benefits3,5283,825Accrued retention43,5851,049,105 Accrued severance Accrued expenses$2,512,25 7. Operating Leases The Company previously leased office and research space in Rockville, Maryland under anoperating lease. During the year ended December 31, 2024, the Company abandoned the leased spaceand recognized an impairment charge of approximately $400,000, representing the carrying value ofthe right-of-use asset. There were no operating leases in place as of March 31, 2025.The components of lease expense and related cash flows were as follows:Three Months Ended March31,20252024Operating lease cost$557$188,310Variable lease cost29,81299,887 8. Stockholders’ EquityCommon Stock During the year ended December 31, 2024, the Company’s board of directors adopted, and itsstockholders approved, an increase in the total authorized shares of common stock from100,000,000 In March 2022, the Company filed a shelf registration statement with the SEC, which was sold under the terms of the Sales Agreement. The shelf registration statement expired on April 28,2025. 9. Stock-based Compensation2013 Equity Incentive Plan The Company’s board of directors adopted, and its stockholders approved, its 2013 Equity employees, consultants and directors. Unless otherwise stated in a stock option agreement,25% of theshares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of oneforty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause,or disability, any vested options shall terminate90 daysafter the termination date, unless otherwise issued and outstanding on the immediately preceding December 31, or such lesser number of sharesas determined by the board of directors or the compensation committee thereof.The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013Plan is20,000,000shares. As of March 31, 2025, the total number of shares reserved for issuanceunder the 2013 Plan was14,257,627shares, of which4,389,042shares were available for future Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares ofcommon stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate Outstanding as of December31,202412,304,882$3.507.4(3,318,69 Outstanding as of March31,2025 64.000.8$—Vested or expected to vest as ofMarch31,20256,278,5295.000.9$—Exercisable as of March31,20255,952,0705.160.7$— ended March 31, 2024 the Company issued2,800shares of common stock and received $4,898in stock as the award vests. The fair value of each RSU is based on the closing price of the Company’scommon stock on the date of grant. In January 2021, the Company awarded RSUs under the 2013Plan to all of its employees. The RSUs vested overfour yearsin equal installments on eachanniversary of the grant date, provided that the employee remained employed by the Company at theapplicable vesting date. Compensation expense is recognized on a straight-line basis. As of March 31, March 31, 2025: Weighted-AverageNumber ofSharesGrant DateUnderlyingRSUsFair ValueUnvested at December31,202448,133$3.81Vested(48,133)3.81Unvested at March31,2025—— nonstatutory stock options, restricted stock awards, RSU awards, stock appreciation rights and otherforms of stock awards to individuals not previously an employee or director of the Company as aninducement for such individuals to join the Company. Unless otherwise stated in an applicable stockoption agreement,one-fourth of the shares subject to an option grant under the Inducement Plan willtypically vest upon the first anniversary of the vesting start date, with the balance of the shares reasons other than death, cause or disability, any vested options will terminate90 daysafter thetermination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate10 yearsfrom the date of grant. The Inducement Plan was amended by the board ofdirectors on multiple occasions to increase the number of shares reserved for issuance to3,000,000 Outstanding as of December31,20240$2.017.1Options forfeited(444,373)1.97Outstanding as of M